Diagnostic Value of Sperm DNA Fragmentation and Sperm Morphology for Assisted Reproduction Treatment
1 other identifier
interventional
N/A
1 country
1
Brief Summary
All patients will go through an ICSI (intracytoplasmic sperm injection)cycle Monitoring: COH (controlled ovarian hyperstimulation) will be monitored by transvaginal sonography, and then the dose of gonadotropin will be adjusted according to the follicle size and number. Triggering ovulation: when three or more follicles reach \>18mm, endometrium triple line \>8mm, both the gonadotropin and agonist injections will be stopped and 10,000 IU of hCG(human chorionic gonadotropin ) will be given. Egg collection : 34-36 hour after hCG injection, embryo transfer :48-72 hour after oocyte retrieval. Luteal phase support: with 100 mg progesterone injection IM daily until the day of the pregnancy test pregnancy test: 15 days after the embryo transfer. Semen collection and preparation Semen samples will be collected by masturbation in clean containers, usually after 2-3 days of abstinence. Each sample will be allowed to liquefy for at least 20 min at 37 °C. Semen analysis: Basic sperm parameters including sperm count, concentration, motility and morphology will be evaluated according to World Health Organization guidelines. After the initial assessment, ejaculates will be divided into three aliquots. An aliquot of each sample will be used to assess sperm DNA damage, the second aliquot will be processed by direct swim-up technique (n 30) or zeta test technique (n 30) this will be followed by assessment of DNA damage again in each sample to measure the difference in DNA damage after processing in each technique then spermatozoa from the third aliquot will be morphologically analyzed manually using Spermic stain and a light microscope and will be scored according to WHO
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Apr 2014
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2014
CompletedFirst Submitted
Initial submission to the registry
August 4, 2015
CompletedFirst Posted
Study publicly available on registry
August 13, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2016
CompletedSeptember 20, 2016
September 1, 2016
2 years
August 4, 2015
September 16, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Percentage of spermatozoa with fragmented DNA before and after processing
Semen samples will be collected by masturbation in clean containers, usually after 2-3 days of abstinence
after taking semen sample by 30 minutes
Secondary Outcomes (1)
reproductive success
pregnancy test done 15 days after the embryo transfer.
Study Arms (2)
swim-up
ACTIVE COMPARATORswim-up technique for semen processing
zeta test
ACTIVE COMPARATORzeta test technique for semen processing
Interventions
Eligibility Criteria
You may qualify if:
- written informed consent for the ICSI treatment
- Female body mass index of 18-30 kg/m2
- No congenital uterine anomalies in gynecological ultrasound of female partner
- Male partner not under pharmacological treatment
- couples undergoes ICSI procedures with ejaculated sperm will be included and - Sperm count not less than 0.1 Million per ML
- Male abstinence period 2-3 days.
You may not qualify if:
- women over 42 years old
- acute infectious diseases
- systemic illnesses
- Treatment cycles that will result in a poor ovarian response (\<3 mature oocytes collected) or those involving epididymal, testicular and cryopreserved sperm samples
- Male patients having varicocele, oligospermia
- male partner under pharmacological treatment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Benha Faculty of Medicine
Banhā, El Qaluobia, 13518, Egypt
Study Officials
- PRINCIPAL INVESTIGATOR
wagdy amer, MD
lecturer
- STUDY CHAIR
abo baker el nashar, MD
professor
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- lecutrer
Study Record Dates
First Submitted
August 4, 2015
First Posted
August 13, 2015
Study Start
April 1, 2014
Primary Completion
April 1, 2016
Study Completion
May 1, 2016
Last Updated
September 20, 2016
Record last verified: 2016-09